13F reference period
Q3 2026
Security Snapshot
Innate Pharma SA - SPONSORED ADS (IPHA) Institutional Ownership
CUSIP: 45781K204
13F Institutional Holders and Ownership History from Q4 2019 to Q3 2026
Institutions Reporting
6
Shares (Excl. Options)
85.71K
Full value: 85,711 · shares · 30 Sep 2026Price
$1.63
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / SPONSORED ADS
- Symbol
- IPHA on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 85,711
- Total 13F value
- $139,709
- Portfolio coverage rank
- 0%
- Share change
- +9,989
- Value change
- +$16,282
- Number of holders
- 6
- SEC-reported price per share
- $1.47
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- IPHA - Innate Pharma SA - SPONSORED ADS is tracked under CUSIP 45781K204.
- 6 institutions reported positions in Q3 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 10 to 6 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$354.05K
Full value: $354,047 · USD · 30 Jun 2026.$139.71K
Full value: $139,709 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 6 institutions filings for Q3 2026.
Security key
45781K204
13F reference period
Q3 2026
13F holders
6
13D/G owners
0
CIK / CUSIP context first
Open Q3 2026 holders
IPHA full holder history
Innate Pharma SA SEC filings
Innate Pharma SA company facts
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45781K204:
As of 30 Sep 2026,
6
institutional investors reported holding
shares of
Innate Pharma SA - SPONSORED ADS (IPHA).
85.71K
Full value: 85,711 · shares · 30 Sep 2026Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Headline period
Q3 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 85,711 | $139,709 | +$16,282 | $1.63 | 6 |
| 2026 Q2 | 192,418 | $354,047 | +$21,202 | $1.84 | 10 |
| 2026 Q1 | 183,951 | $235,456 | -$131,534 | $1.28 | 9 |
| 2025 Q4 | 276,273 | $483,479 | +$336,530 | $1.75 | 11 |
| 2025 Q3 | 81,617 | $157,932 | -$33,200 | $1.93 | 9 |
| 2025 Q2 | 99,838 | $179,124 | -$103,610 | $1.81 | 9 |
| 2025 Q1 | 158,189 | $282,029 | +$35,950 | $1.78 | 10 |
| 2024 Q4 | 137,970 | $255,200 | -$185,232 | $1.85 | 9 |
| 2024 Q3 | 237,742 | $544,429 | -$8,244 | $2.29 | 7 |
| 2024 Q2 | 241,754 | $469,203 | -$47,224 | $1.94 | 8 |
| 2024 Q1 | 253,918 | $731,097 | +$360,018 | $2.88 | 9 |
| 2023 Q4 | 128,912 | $360,800 | -$530,587 | $2.80 | 8 |
| 2023 Q3 | 318,407 | $805,527 | +$202,235 | $2.53 | 8 |
| 2023 Q2 | 234,858 | $734,353 | -$489,953 | $3.14 | 8 |
| 2023 Q1 | 396,953 | $1,128,356 | -$11,741 | $2.85 | 8 |
| 2022 Q4 | 399,345 | $1,489,515 | -$1,137,189 | $3.73 | 9 |
| 2022 Q3 | 944,107 | $1,889,000 | -$25,335 | $2.00 | 9 |
| 2022 Q2 | 954,312 | $2,576,000 | -$75,845 | $2.70 | 12 |
| 2022 Q1 | 952,242 | $3,199,000 | -$1,450,749 | $3.36 | 12 |
| 2021 Q4 | 1,281,081 | $5,847,000 | +$940,213 | $4.56 | 15 |
| 2021 Q3 | 943,114 | $5,818,000 | +$5,267,159 | $6.17 | 18 |
| 2021 Q2 | 89,540 | $296,000 | -$324,286 | $3.30 | 5 |
| 2021 Q1 | 176,028 | $759,802 | -$5,091,420 | $4.32 | 7 |
| 2020 Q4 | 1,395,579 | $5,707,000 | -$1,116,725 | $4.09 | 4 |
| 2020 Q3 | 1,683,925 | $6,652,000 | -$6,064,054 | $3.90 | 6 |